➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Mallinckrodt
Harvard Business School
Colorcon
AstraZeneca

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

BYNFEZIA PEN Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Bynfezia Pen patents expire, and what generic alternatives are available?

Bynfezia Pen is a drug marketed by Sun Pharm and is included in one NDA. There is one patent protecting this drug.

This drug has five patent family members in five countries.

The generic ingredient in BYNFEZIA PEN is octreotide acetate. There are twenty drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Bynfezia Pen

A generic version of BYNFEZIA PEN was approved as octreotide acetate by WEST-WARD PHARMS INT on April 8th, 2005.

  Try Before You Buy

Summary for BYNFEZIA PEN
International Patents:5
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in BYNFEZIA PEN?BYNFEZIA PEN excipients list
DailyMed Link:BYNFEZIA PEN at DailyMed
Drug patent expirations by year for BYNFEZIA PEN

US Patents and Regulatory Information for BYNFEZIA PEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm BYNFEZIA PEN octreotide acetate SOLUTION;SUBCUTANEOUS 213224-001 Jan 28, 2020 RX Yes Yes   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Baxter
McKesson
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.